Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?

被引：0
|
作者：
Kubilay Karaboyun
Eyyup Cavdar
Yakup Irıagac
Abdussamet Celebı
Tanju Kapagan
Ilkay Gulturk
Ozden Demır
Okan Avcı
Erdogan Selcuk Seber
机构：
[1] Tekirdag Namik Kemal University,Department of Medical Oncology, School of Medicine
[2] Marmara University,Department of Medical Oncology, School of Medicine
[3] Basaksehir Cam and Sakura City Hospital,Department of Medical Oncology
[4] Bakirkoy Dr. Sadi Konuk Training and Research Hospital,Department of Medical Oncology
[5] Ondokuz Mayıs University,Department of Medical Oncology, School of Medicine
来源：
Supportive Care in Cancer | 2023年 / 31卷
关键词：
Urinary Incontinence; Early breast cancer; Adjuvant hormone therapy; Tamoxifen; Aromatase inhibitor; ICIQ-UI SF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
    Karaboyun, Kubilay
    Cavdar, Eyyup
    Iriagac, Yakup
    Celebi, Abdussamet
    Kapagan, Tanju
    Gulturk, Ilkay
    Demir, Ozden
    Avci, Okan
    Seber, Erdogan Selcuk
    SUPPORTIVE CARE IN CANCER, 2023, 31 (06)
  • [2] Adherence challenges in breast cancer: Evaluating tamoxifen and aromatase inhibitors in adjuvant hormone therapy
    Camejo, N.
    Amarillo, D.
    Castillo, C.
    Argenzio, L.
    Santana, D.
    Herrera, G.
    Cabrera, L.
    Guerrina, M.
    Dorner, C.
    Krygier, G.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 35 - 36
  • [3] Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
    Holm Eggemann
    Atanas Ignatov
    Bobbie J. Smith
    Udo Altmann
    Gunter von Minckwitz
    Freidrich W. Röhl
    Mark Jahn
    Serban-Dan Costa
    Breast Cancer Research and Treatment, 2013, 137 : 465 - 470
  • [4] Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
    Eggemann, Holm
    Ignatov, Atanas
    Smith, Bobbie J.
    Altmann, Udo
    von Minckwitz, Gunter
    Roehl, Freidrich W.
    Jahn, Mark
    Costa, Serban-Dan
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 465 - 470
  • [5] Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer
    Perez, E. A.
    ANNALS OF ONCOLOGY, 2007, 18 : 26 - 35
  • [6] Visual Impairment in Myopic Patients With Breast Cancer Receiving Adjuvant Therapy With Aromatase Inhibitors
    Epstein, Richard J.
    CLINICAL BREAST CANCER, 2009, 9 (03) : 184 - 186
  • [7] Aromatase inhibitors in adjuvant therapy of breast cancer: Before, instead of, or beyond tamoxifen
    Pritchard, KI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 4850 - 4852
  • [8] Tamoxifen versus aromatase inhibitors as adjuvant therapy in premenopausal women with hormone receptor-positive breast cancer: Effects on sexuality and the female reproductive system
    Skolariki, A.
    Boutis, A.
    Kosmidis, E. K.
    ANNALS OF ONCOLOGY, 2020, 31 : S45 - S45
  • [9] Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
    Dackus, Gwen M. H. E.
    Jozwiak, Katarzyna
    Sonke, Gabe S.
    van der Wall, Elsken
    van Diest, Paul J.
    Siesling, Sabine
    Hauptmann, Michael
    Linn, Sabine C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (11): : 1506 - 1514
  • [10] Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer
    van de Velde, C. J. H.
    Verma, S.
    van Nes, J. G. H.
    Masterman, C.
    Pritchard, K. I.
    CANCER TREATMENT REVIEWS, 2010, 36 (01) : 54 - 62
12345